In this review:
Reduced duration trastuzumab for HER2-positive early BC
Veliparib + carboplatin in TNBC
Neoadjuvant and adjuvant pembrolizumab for early-stage TNBC
Abemaciclib + endocrine therapy for high-risk early BC
Trastuzumab deruxtecan vs trastuzumab emtansine for HER2-positive metastatic BC
Intracranial activity of trastuzumab deruxtecan in HER2-positive BC
Ribociclib + endocrine for hormone receptor positive, HER2-negative advanced BC
Giredestrant + palbociclib in ER-positive, HER2-negative BC
Pembrolizumab + chemotherapy for metastatic TNBC
Palbociclib in hormone receptor-positive/ HER2-negative metastatic BC
Please login below to download this issue (PDF)